Comment lutter efficacement contre les taches brunes ? Causées principalement par le soleil, les taches brunes peuvent ...

Based on these data, iSCIB1+ has been selected for future development expanding the addressable patients to around 80% of late-stage melanoma patients and with longer patent life. Development plans ...

About BK polyomavirus in kidney transplant recipients More than 100,000 kidney transplants are conducted worldwide every year. BKPyV can become reactivated in up to 50% of these patients and up to 70% ...

Novo Nordisk announced the expansion of its Health Ecosystem Alliance, first introduced in 2023. Fangzhou was named an “Outstanding Strategic Health Ecosystem Partner,” recognizing its role in ...

This week, React19 announced the launch of ‘This Is Our Shot,’ a nationwide campaign to raise over $1 million for additional care grants. Two anonymous benefactors have pledged $250,000 each, creating ...

HomeInherit provides ethical and transparent financial solutions that allow seniors to unlock home equity without taking on debt. With a focus on trust, family inclusion, and clear communication, ...

SRx Health Solutions, Inc. (NYSE American: SRXH) (the “Company”) today announced the Company has been notified by the NYSE American of unusual trading activity of its Common Shares on November 6, 2025 ...

The Company anticipates no change to the preliminary sales results for the third quarter ended September 30, 2025 that were disclosed on October 7, 2025. The Company expects to file its Quarterly ...

Operating results Total operating expenses were approximately $12.1 million for the three months ended September 30, 2025, a decrease of $0.7 million from $12.8 million for the same period in 2024.

Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot ...

Net revenue increased 35% to $4.8 million compared to $3.5 million in the third quarter of 2024 Net income increased 84% to $337,000, compared to $183,000 in the third quarter of 2024 Adjusted EBITDA ...

2025 Financial Guidance Sight Sciences raises its revenue guidance expectations for full year 2025 to $76.0 million to $78.0 million, representing a 2% to 5% decline compared to full year 2024 revenue ...